2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Zoufang Huang, Vivek P. Chavda*, Lalitkumar K. Vora, Normi Gajjar, Vasso Apostolopoulos, Nirav Shah, Zhe Sheng Chen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

62 Downloads (Pure)

Abstract

Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.

Original languageEnglish
Article number899633
Number of pages10
JournalFrontiers in Pharmacology
Volume13
DOIs
Publication statusPublished - 12 Apr 2022

Bibliographical note

Funding Information:
VC wants to dedicate this work to L M College of pharmacy as a part of the 75th year celebration of the college. The authors would like to acknowledge Prachi Bendale (School of Pharmacy, Queen’s University Belfast, United Kingdom) and Sita V. G, for peer-reviewing the manuscript and providing his valuable input to refine the manuscript. VA acknowledges the support of the Victoria University Planetary Health grant (PH098) and the Immunology and Translational research group, Victoria University, Australia.

Funding Information:
VC wants to dedicate this work to L M College of pharmacy as a part of the 75th year celebration of the college. The authors would like to acknowledge Prachi Bendale (School of Pharmacy, Queen?s University Belfast, United Kingdom) and Sita V. G, for peer-reviewing the manuscript and providing his valuable input to refine the manuscript. VA acknowledges the support of the Victoria University Planetary Health grant (PH098) and the Immunology and Translational research group, Victoria University, Australia.

Publisher Copyright:
Copyright © 2022 Huang, Chavda, Vora, Gajjar, Apostolopoulos, Shah and Chen.

Keywords

  • 2-deoxy-D-glucose
  • 2-DG, COVID-19
  • coronavirus
  • glycolysis
  • SARS-CoV-2
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of '2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update'. Together they form a unique fingerprint.

Cite this